KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state
P den mde bevarer du kontrollen, og du kan gradvist finjustere din strategi, alt efter hvordan din smag udvikler sig over tid og hvilke formater, du synes leverer den bedste kombination af underholdning og vrdi
Currently, the FDA has approved three GLP-1 RAs for obesity treatment: liraglutide, semaglutide and tirzepatide
Tirzepatide (Mounjaro), a dual GLP-1/GIP receptor agonist, received UK approval for type 2 diabetes and is under evaluation for obesity treatment
Study #2: Menstrual cycle regularity The same meta-analysis found significant improvement in menstrual regularity (SMD: 1.72, P 15 pounds during washout: This suggests intervention needed: Reassess calorie intake (are you eating significantly more than maintenance?) Increase protein target to 120-150g daily Add resistance training if not already doing it Consider extended washout (4 months instead of 3) to stabilize weight Meet with dietitian for structured meal plan Important consideration: Significant weight regain may impact the fertility improvements you gained from GLP-1 use